The Evaluation of Recombinant LH Supplementation in Patients With Suboptimal Response to Recombinant FSH Undergoing ICSI

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

The investigators aimed to evaluate patients who had In-vitro fertilization treatment and who had COH (controlled ovarian hyperstimulation) cycles applying long protocol with GnRH (gonadotropin-releasing hormone) analogue with suboptimal response to the rFSH. The investigators evaluated and compared the addition of rLH, increasing the dose of rFSH and the control groups regarding the results of IVF in these patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sisli Etfal Training & Research Hospital; Sisli Hamidiye Etfal Training and Research Hospital
• Collaborator: Selcuk University

Criteria

Inclusion Criteria:

• Patients aged 23-39

• Body mass index between 18 and 30 kg/m2

• Baseline FSH ≤12 IU/l, E2 ≤ 80 pg/ml

• The presence of both ovaries and uterine cavity capable of sustaining a pregnancy

• Who had regular menstrual cycles (21-35 days) Confirmed absence of pregnancy and sufficient number of antral follicles on the transvaginal US examination on the 3rd day of menstruation

• Who were having their first or second IVF trial.

Exclusion Criteria:

• Grade III-IV endometriosis

• Clinically significant condition preventing them from undergoing gonadotrophin treatment

• More than two previous assisted cycles

• Who had a single ovary

• Unexplained gynaecological bleeding

• Polycystic ovary or an ovarian cyst of unknown aetiology

• Previously diagnosed with a space occupying lesion like submucous myoma , polyps, septum, synechia in the uterine cavity

• Have a chromosomal anomaly.